Enliven Therapeutics, Inc.
NASDAQ:ELVN
Overview | Financials
Company Name | Enliven Therapeutics, Inc. |
Symbol | ELVN |
Currency | USD |
Price | 28.66 |
Market Cap | 1,353,818,152 |
Dividend Yield | 0% |
52-week-range | 9.8 - 30.03 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Samuel S. Kintz M.B.A. |
Website | https://www.enliventherapeutics.com |
An error occurred while fetching data.
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD